Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) serves as a notification to the U.S. Securities and Exchange Commission regarding the submission of its Annual Report on Form 20-F. The filing was made on March 6, 2020, and covers the audited financial statements for the fiscal year ended December 31, 2019.
Key Financial Metrics
The provided text does not contain specific financial data. It acts solely as a cover document announcing the availability of the full Annual Report. Consequently, values for revenue, profit, cash flow, margins, debt, and liquidity are not present in this filing text.
Material Changes
No material changes or comparative financial analysis are included in this document. The filing references the 2019 Annual Report for detailed financial performance but does not summarize year-over-year changes within this text.
Guidance, Outlook, and Risks
The filing includes a cautionary statement regarding forward-looking statements. GSK notes that any projections are subject to risks and uncertainties that could cause actual results to differ materially. Specific risk factors are referenced as being detailed in Item 3.D of the 2019 Annual Report on Form 20-F. No specific guidance or management commentary on future outlook is provided in this summary text.
Investor Verification Checklist
- Verify the full audited financial statements for the year ended December 31, 2019, by accessing the Form 20-F on the SEC website or GSK's corporate reporting portal.
- Review Item 3.D "Risk factors" in the 2019 Annual Report to understand the specific uncertainties affecting forward-looking statements.
- Confirm the date of the Annual General Meeting and the availability of hard copy reports, noted as available on or about March 23, 2020.
- Check the registrars (Equiniti Limited) and ADR depositary (J.P. Morgan Chase Bank, N.A.) contact details for shareholder services.